SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001479290-20-000050
Filing Date
2020-03-26
Accepted
2020-03-26 17:08:38
Documents
5
Effectiveness Date
2020-03-26

Document Format Files

Seq Description Document Type Size
1 DEFA14A rvnc2020proxystatementdefa.htm DEFA14A 30236
2 revance2020proxynoticepage1o.jpg GRAPHIC 349075
3 revance2020proxynoticepage2.jpg GRAPHIC 230760
4 revance2020proxynoticepage3.jpg GRAPHIC 80434
5 revance2020proxynoticepage4.jpg GRAPHIC 52098
  Complete submission text file 0001479290-20-000050.txt   975710
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36297 | Film No.: 20746879
SIC: 2834 Pharmaceutical Preparations